⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25006051 | 1.00 | — | — | |
| SCHEMBL25113460 | 1.00 | — | — | |
| SCHEMBL20233856 | 1.00 | — | — | |
| SCHEMBL999402 | 0.95 | — | — | |
| SCHEMBL1263364 | 0.92 | — | — | |
| SCHEMBL2422200 | 0.86 | ALDH1A1 (0.32) | — | |
| SCHEMBL21765789 | 0.85 | ADRB2 (0.31) | — | |
| SCHEMBL10447832 | 0.85 | ODC1 (0.36) | — | |
| SCHEMBL25602000 | 0.85 | ODC1 (0.36) | — | |
| SCHEMBL17167688 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118021978-A | GHRH antagonists for use in methods of treating sarcoidosis | 迈阿密大学 | 2024-05-14 | — | — | CN | claimed |
| EP-4331674-A2 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | University of Miami (US) | 2024-03-06 | — | — | EP | claimed |
| US-11851468-B2 | Treatment of neurological diseases | UNIVERSITY OF LANCASTER (GB) | 2023-12-26 | — | — | US | claimed |
| US-20230287051-A1 | INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES | ZEALAND PHARMA A/S (DK) | 2023-09-14 | — | — | US | claimed |
| EP-3999095-B1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | UNIV MIAMI (US) | 2023-09-13 | — | — | EP | claimed |
| CN-116209671-A | Inhibitors of complement factor C3 and medical uses thereof | 西兰制药第三特殊目的公司 | 2023-06-02 | — | — | CN | claimed |
| EP-4182023-A1 | INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES | ZP SPV 3 K/S (DK) | 2023-05-24 | — | — | EP | claimed |
| US-11382956-B2 | Amylin analogues | ZEALAND PHARMA A/S (DK) | 2022-07-12 | — | — | US | claimed |
| EP-3999095-A1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | University of Miami (US) | 2022-05-25 | — | — | EP | claimed |
| US-20220143149-A1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-05-12 | — | — | US | claimed |
| EP-1718665-A4 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS INC (US) | 2008-05-14 | — | — | EP | claimed |
| WO-2008021560-A2 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| EP-1853627-A2 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | Amylin Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| JP-2007525495-A | — | — | 2007-09-06 | — | — | JP | claimed |
| WO-2007022123-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-20060293232-A1 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-12-28 | — | — | US | claimed |
| EP-1718665-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | Amylin Pharmaceuticals, Inc. (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2006086769-A2 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-20060094652-A1 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | claimed |
| WO-2005077072-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | WO | claimed |